Opus Genetics, Inc.
About Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. Its pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration. Opus Genetics is a public company (Nasdaq: IRD) and a subsidiary of Ocuphire Pharma, Inc., headquartered in Raleigh, NC.
- 🔗 Opus Genetics, Inc.
- 🔗 Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - Oberland Capital
- 🔗 Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update :: Opus Genetics, Inc. (Nasdaq:IRD)
- 🔗 Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- 🔗 Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Investors
Key highlights
- Secured up to $155M non-dilutive financing facility from Oberland Capital with $35M initial tranche funded.
- Maintains cash position of $88.8M as of June 30, 2026, expected to fund operations into 2029.
- Developing seven AAV-based gene therapy programs for inherited retinal diseases including OPGx-LCA5 and OPGx-BEST1.
- Publicly traded on Nasdaq under ticker IRD with total historical funding of $161.76M.
Ask StreetZero about Opus Genetics, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account